Navigation Links
Savient Pharmaceuticals Announces Search for CEO
Date:12/28/2010

EAST BRUNSWICK, N.J., Dec. 28, 2010 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its Board of Directors has initiated a search for a Chief Executive Officer.  Paul Hamelin, Savient's President since November 2008 and its most senior executive officer, will continue to lead the day-to-day operations of the company until Savient hires a CEO.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

FORWARD LOOKING STATEMENTS

Any statements contained in this release that are not historical facts are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements regarding the search for a chief executive officer and the continuing role of Paul Hamelin are forward-looking statements.  All forward-looking statements rely on assumptions and are subject to various risks and uncertainties that could ca
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXAâ„¢ for Prescription and Reports Third Quarter 2010 Financial Results
3. Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
4. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
5. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
6. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
7. Savient Pharmaceuticals To Hold First Quarter 2010 Results
8. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
11. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... June 22, 2007 /PRNewswire/ -- MAP,Pharmaceuticals, Inc. today ... its Unit Dose Budesonide (UDB) pediatric asthma therapy,clinical ... Lutfi Kirdar,Convention and Exhibition Center in Istanbul, Turkey. ... and safety,of a novel submicron particle formulation of ...
... Announces Bioinformatics Partnership with,Illumina , BEYOND GENOME ... a leading developer of lab and data ... announced that,it has penned an agreement with ... participant in IlluminaConnect, a,bioinformatics software program established ...
Cached Medicine Technology:MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting 2GenoLogics Announces Bioinformatics Partnership with Illumina 2GenoLogics Announces Bioinformatics Partnership with Illumina 3
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... Oxygen", as it is known by researchers at the Norwegian ... is gained on the pitch thanks to their new system ... the Journal of Sports Medicine and has enjoyed ... improve the players, sprint, jump and endurance. , "With ...
... near manufacturing industries, a breath of air may ... location, finds a recent study involving a Kansas ... of geology at Kansas State University, along with ... School of Public Health and Department of Environmental ...
... Measurement of pressure within the eye, or intraocular pressure (IOP), ... in patients with glaucoma are believed to be related to ... to the optic nerve and vision. The clinical assessment ... daytime hours. In a new study, parents using the ...
... Steven Reinberg HealthDay Reporter , TUESDAY, March ... who have psychiatric disorders, especially post-traumatic stress disorder, are ... narcotic painkillers, a new study finds. Use of ... Vicodin, can become addictive and cause more serious problems, ...
... (HealthDay News) -- Most stroke patients undergo both CT and ... rising costs of stroke care in the United States, a ... from more than 600,000 patients diagnosed with stroke between 1999 ... of the patients who had MRI scans also had CT ...
... (HealthDay News) -- When it comes to wine, a new study ... on many consumers. The professionals seem to have a much ... State University explained. As a result, wine experts are able to ... people just can,t taste. "What we found is that the ...
Cached Medicine News:Health News:1 more 'player' on the pitch thanks to a new training method 2Health News:Manganese concentrations higher in residential neighborhoods than industrial sites, varies by region 2Health News:Manganese concentrations higher in residential neighborhoods than industrial sites, varies by region 3Health News:Home measurement of eye pressure in children may improve management of glaucoma 2Health News:Narcotic Painkillers Another Threat to Traumatized War Vets: Study 2Health News:Narcotic Painkillers Another Threat to Traumatized War Vets: Study 3Health News:Brain Scans Overused on U.S. Stroke Patients, Study Says 2Health News:Wine Ratings May Be Meaningless for Most People 2
Features soft, low friction sheath that extends beyond the tip....
Designed to retain the desired curve during oral intubation....
Facilitates intubation of tracheal tubes....
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box....
Medicine Products: